Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study

We investigated Favipiravir (FPV) efficacy in mild cases of COVID-19 without pneumonia and its effects towards viral clearance, clinical condition, and risk of COVID-19 pneumonia development. PCR-confirmed SARS-CoV-2-infected patients without pneumonia were enrolled (2:1) within 10 days of symptomat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirijatuphat, Rujipas, Manosuthi, Weerawat, Niyomnaitham, Suvimol, Owen, Andrew, Copeland, Katherine Kradangna, Charoenpong, Lantharita, Rattanasompattikul, Manoch, Mahasirimongkol, Surakameth, Wichukchinda, Nuanjun, Chokephaibulkit, Kulkanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronaviruses
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518247/
https://www.ncbi.nlm.nih.gov/pubmed/35997325
http://dx.doi.org/10.1080/22221751.2022.2117092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518247/
https://www.ncbi.nlm.nih.gov/pubmed/35997325
http://dx.doi.org/10.1080/22221751.2022.2117092

Ejemplares similares